NeuroSense Therapeutics Ltd. NRSN
6.95
(0.45)
(6.08%)
as of 25 Sep
- Market cap
- $14.0M
- P/E
- 0.0×
Follow NRSN
Insider Buys
alert about insiders buying in the last 12 month
| Jun '25 | Sep '24 | Jun '24 | Mar '24 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
0.71 | 0.21 | 0.46 | 0.26 |
+8 more quarters Free account |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.24 | |
Debt/Assets |
0.00% | 1.93% | 1.96% | 3.80% | |
Debt/Equity |
0.00 | (0.01) | (0.02) | (0.01) | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | — | 0.00 | 0.00 | |
Capex/Depreciation |
(0.62) | — | (0.27) | — | |
Interest Coverage |
— | — | — | 0.00 | |
Research and Development Expense of Revenue |
— | — | — | 0.00% | |
Selling, General and Administrative Expense of Revenue |
— | — | — | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | — | 0.00% | — | |
Free Cash Flow per Share |
0.00 | — | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 1.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | (9.08) | |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | (9.08) | |
Free Cash Flow |
(4.00) | — | (5.75) | — | |
Working Capital |
(0.65) | (3.00) | (1.89) | (3.34) | |
Capital Expenditures |
0.00 | — | 0.00 | — | |
Net Current Asset Value |
(0.65) | (3.02) | (1.92) | (7.25) | |
| Other line items | |||||
Quick Ratio |
0.71 | 0.21 | 0.46 | 0.26 | |
Revenue per Share |
— | — | — | 0.00 | |
Operating CF per Share |
0.00 | — | 0.00 | 0.00 | |
Capex per Share |
0.00 | — | 0.00 | 0.00 | |
Average Receivables |
0.54 | 0.36 | 0.41 | 0.49 | |
Average Payables |
1.28 | 1.15 | 1.29 | 1.40 | |
Average Assets |
2.43 | 3.19 | 4.85 | 3.39 | |
Average Common Equity |
(1.14) | (1.51) | (1.62) | (2.05) | |
Capex to Sales |
0.00 | — | 0.00 | — | |
Net Profit Margin |
— | — | — | 0.00% |
Columns are period end dates